Real-Life Experience of Hepatitis C Treatment with Direct-Acting Antivirals in Genotypes 2 and 3
Turkish Journal of Gastroenterology · 2025
DOI: 10.5152/tjg.2025.24751 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Turkish Journal of Gastroenterology, 2025. Verfasst von Sibel Yıldız Kaya und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Disease and Clinical Microbiology, İstanbul University Cerrahpaşa Faculty of Medicine, İstanbul, Türkiye. Hauptthemen laut MEDLINE: Antiviral Agents, Hepacivirus, Hepatitis C, Chronic. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background/Aims: This study evaluates the efficacy and safety of direct-acting antivirals (DAAs) in treating hepatitis C virus (HCV) genotype 2 (GT-2) and genotype 3 (GT-3) in Türkiye. Materials and Methods: This cohort is a multicenter, retrospective, and observational study. Data from 267 GT-2 or GT-3 patients treated with a DAA were analyzed.
Results
An overall sustained virological response (SVR) rate of 95.9%, with no significant difference between GTs. The SVR rates were relatively lower in patients with cirrhosis. Prior pegylated interferon and ribavirin reduced SVR rates, particularly in males and patients with cirrhosis. The most common treatments were sofosbuvir-based regimens, which demonstrated comparable efficacy. No significant drug interactions were observed. The most commonly reported adverse events were fatigue and mild anemia, particularly in cirrhotic patients; however, these did not lead to treatment discontinuation.
Conclusion
This study supports the efficacy and tolerability of DAA regimens for these HCV GTs, thereby reinforcing their role in HCV eradication. Cite this article as: Kaya SY, Kurtaran B, Çuvalcı NÖ, et al. Real-life experience of hepatitis C treatment with direct-acting antivirals in genotypes 2 and 3. Turk J Gastroenterol. Published online September 10, 2025. doi: 10.5152/tjg.2025.24751.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Infectious Disease and Clinical Microbiology, İstanbul University Cerrahpaşa Faculty of Medicine, İstanbul, Türkiye.
- Department of Infectious Disease and Clinical Microbiology, Çukurova University Faculty of Medicine, Adana, Türkiye.
- Department of Infectious Disease and Clinical Microbiology, Antalya Training and Research Hospital, Antalya, Türkiye.
- Department of Infectious Disease and Clinical Microbiology, Mustafa Kemal University Faculty of Medicine, Hatay, Türkiye.
- Department of Infectious Disease and Clinical Microbiology, Harran University Faculty of Medicine, Şanlıurfa, Türkiye.
- Department of Infectious Disease and Clinical Microbiology, Haseki Training and Research Hospital, İstanbul, Türkiye.
ORCID-Profile: Sibel Yıldız Kaya, Behice Kurtaran, Nefise Öztoprak Çuvalcı, Yusuf Önlen, Mehmet Reşat Ceylan, Esra Zerdali, Nagehan Didem Sarı, Ahsen Öncül, Nurettin Erben, Ayse Batirel, Dilara İnan, Süheyla Kömür, Figen Sarıgül Yıldırım, Hasibullah Yaqoobi, Ferit Kuscu, Rahmet Guner, Fehmi Tabak
Zitieren
APA
Kaya, S. Y., Kurtaran, B., Çuvalcı, N. Ö., Önlen, Y., Ceylan, M. R., Zerdali, E., Sarı, N. D., Öncül, A., Erben, N., Batirel, A., İnan, D., Kömür, S., Yıldırım, F. S., Yaqoobi, H., Kuscu, F., Guner, R., Tabak, F., & Hep-C Türkiye Study Group (2025). Real-Life Experience of Hepatitis C Treatment with Direct-Acting Antivirals in Genotypes 2 and 3. Turkish Journal of Gastroenterology. https://doi.org/10.5152/tjg.2025.24751
Vancouver
Kaya SY, Kurtaran B, Çuvalcı NÖ, Önlen Y, Ceylan MR, Zerdali E, et al. Real-Life Experience of Hepatitis C Treatment with Direct-Acting Antivirals in Genotypes 2 and 3. Turkish Journal of Gastroenterology. 2025. doi:10.5152/tjg.2025.24751
BibTeX
@article{Kaya2025,
author = {Kaya, Sibel Yıldız and Kurtaran, Behice and Çuvalcı, Nefise Öztoprak and Önlen, Yusuf and Ceylan, Mehmet Reşat and Zerdali, Esra and Sarı, Nagehan Didem and Öncül, Ahsen and Erben, Nurettin and Batirel, Ayse and İnan, Dilara and Kömür, Süheyla and Yıldırım, Figen Sarıgül and Yaqoobi, Hasibullah and Kuscu, Ferit and Guner, Rahmet and Tabak, Fehmi and Hep-C Türkiye Study Group, Hep-C Türkiye Study Group},
title = {Real-Life Experience of Hepatitis C Treatment with Direct-Acting Antivirals in Genotypes 2 and 3},
journal = {Turkish Journal of Gastroenterology},
year = {2025},
doi = {10.5152/tjg.2025.24751}
}
EUVIMED